Genetic analysis of candidate genes for the polycystic ovary syndrome

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 6, 2002, Pages 492-501

  Urbanek, Margrit ^a   Spielman, Richard S ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ANDROGEN RECEPTOR; CALPAIN; CYSTEINE PROTEINASE; FOLLISTATIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2;

ALLELE; CHROMOSOME ANALYSIS; DNA POLYMORPHISM; FAMILIAL DISEASE; GENE FUNCTION; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE LOCUS; GENETIC ANALYSIS; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC MARKER; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HORMONE ACTION; HUMAN; HUMAN GENOME; INHERITANCE; MEDICAL GENETICS; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; PROTEIN ANALYSIS; PROTEIN DOMAIN; REVIEW; RISK FACTOR; STEROIDOGENESIS; TRANSACTIVATION; VARIABLE NUMBER OF TANDEM REPEAT; X CHROMOSOME;

EID: 0038348532     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200212000-00009     Document Type: Review

References (119)

1. Risch N: Searching for genetic determinants in the new millenium. Nature 2000, 405:847-856. This article is an insightful review of genetic analysis of complex genetic disorders.
2. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993, 52:506-516.
3. Thomson G: Mapping disease genes: family-based association studies. Am J Hum Genet 1995, 57:487-498.
4. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al.: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83:3078-3082.
5. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al.: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84:4006-4011.
6. Zawadski JK, Dunaif A: Diagnostic Criteria for polycystic ovary syndrome: Towards a rational approach. In The Polycystic Ovary Syndrome. Edited by Merriam G. Cambridge MA: Blackwell Scientific; 1992: pp. 377-384.
7. Hoeger K: Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001, 28:85-97, vi-vii.
8. Dunaif A, Graf M, Mandeli J, et al.: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987, 65:499-507.
9. Dunaif A, Segal KR, Futterweit W, et al.: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
10. Cotrozzi G, Matteini M, Relli P, et al.: Hyperinsulinism and insulin resistance in polycystic ovarian syndrome: a verification using oral glucose, IV Glucose and tolbutamide. Acta Diabetol Lat 1983, 20:135-142.
11. Ehrmann DA, Sturis J, Byrne MM, et al.: Insulin secretory defects in polycystic ovary syndrome, relation to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995, 96:520-527.
12. Legro RS, Kunselman A, Dodson WC, et al.: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-169.
13. Talbott EO, Guzick DS, Sutton-Tyrell K: Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterio Vasc Bio 2000, 20:2414-2421.
14. Legro RS, Spielman R, Urbanek M, et al.: Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 1998, 53:217-256.
15. Carey AH, Chan KI, Short F, et al.: Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol 1993, 38:653-658.
16. Legro RS, Driscoll D, Strauss JF, et al.: Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998, 95:14956-14960.
17. Kahsar-Miller M, Azziz R: Heritability and the risk of developing androgen excess. J Steroid Biochem Mol Biol 1999, 69:261-268.
18. Cooper HE, Spellacy WN, Prem KA, et al.: Hereditary factors in Stein-Leventhal syndrome. Am J Obstet Gynecol 1968, 100:371-387. First systematic evaluation of familial transmission of phenotypic characteristics of PCOS.
19. Ferriman D, Purdie AW: The inheritance of polycystic ovarian disease and a possible relation to premature balding. Clin Endocrinol (Oxf) 1979, 11:291-300.
20. Jahanfar S, Eden JA, Warren P, et al.: A twin study of polycystic ovary syndrome. Fertil Steril 1995, 63:478-486.
21. Givens JR: Familial polycystic ovarian disease. Endocrinol Metab Clin N Am 1988, 17:771-783.
22. Hague W, Adams J, Reeders S, et al.: Familial polycystic ovaries: A genetic disease. Clin Endocrinol 1988, 29:593-605.
23. Kahsar-Miller MD, Nixon C, Boots LR, et al.: Prevalence of polycystic ovary syndrome (PCOS) in first degree relatives of patients with PCOS. Fertil Steril 2001, 75:53-58.
24. Legro RS: Polycystic ovary syndrome: the new millenium. Mol Cell Endocrinol 2002, 186:219-225.
25. Urbanek M, Legro RS, Driscoll DA, et al.: Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999, 96:8573-8578. A complete survey of the role of 37 candidate genes in the etiology of PCOS. One of the few studies that tests for both linkage and association.
26. Heinonen S, Korhonen S, Hippelainen M, et al.: Apolipoprotein E alleles in women with polycystic ovary syndrome. Fertil Steril 2001, 75:878-880.
27. Legro R, Shahbahrami B, Lobo R, et al.: Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994, 83:701-706.
28. Mifsud A, Ramirez S, Yong EL: Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000, 85:3484-3488.
29. Hickey T, Chandy A, Norman RJ: The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:161-165.
30. Ehrmann DA, Schwarz PE, Hara M, et al.: relation of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:1669-1673.
31. Haddad L, Evans JC, Gharani N, et al.: Variation within the Type 2 Diabetes Susceptibility Gene Calpain-10 and Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2002, 87:2606-2610.
32. Gharani N, Waterworth DM, Batty S, et al.: Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997, 6:397-402. First report to show genetic evidence for CYP11a as a susceptibility gene for PCOS.
33. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, et al.: Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000, 73:735-741.
34. San Millan JL, Sancho J, Calvo RM, et al.: Role of the pentanuclectide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 2001, 75:797-802.
35. Techatraisak K, Conway GS, Rumsby G: Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol 1997, 46:131-134.
36. Gharani N, Waterworth DM, Williamson R, et al.: 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab 1996, 81:4174.
37. Marszalek B, Lacinski M, Babych N, et al.: Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001, 15:123-128.
38. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, et al.: Polymorphism T->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999, 71:431-435.
39. Tucci S, Futterweit W, Concepcion FS, et al.: Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metabol 2001, 86:446-449.
40. Witchel SF, Aston CE: The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Ped Endocrinol Metab 2000, 13:1315-1317.
41. Kahsar-Miller M, Boots LR, Azziz R: Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome. Fertil Steril 1999, 71:436-438.
42. Legro R, Muhleman D, Comings D, et al.: A dopamine D3 receptor genotype is associated with hyperandrogenic chronic anovulation and resistant to ovulation induction with clomiphene citrate in female Hispanics. Fertil Steril 1995, 63:779-784.
43. Liao WX, Roy AC, Ng SC: Preliminary investigation of follistatin gene mutations in women with polycystic ovary syndrome. Mol Hum Reprod 1999, 6:587-590.
44. Urbanek M, Wu X, Vickery KR, et al.: Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85:4455-4461. Follow-up analysis of follistatin results reported in Urbanek et al 1999. Illustrates importance of follow-up analysis of even highly significant findings when they are based on small sample sizes.
45. Takakura K, Takebayashi K, Wang HQ, et al.: Follicle-stimulating hormone receptor gene mutations are rare in Japanese women with premature ovarian failure and polycystic ovary syndrome. Fertil Steril 2001, 75:207-209.
46. Tong Y, Liao WX, Roy AC, et al.: Absence of mutations in the coding regions of follicle-stimulating hormone receptor gene in Singapore Chinese women with premature ovarian failure and polycystic ovary syndrome. Horm Metab Res 2001, 33:221-226.
47. Tong Y, Liao WX, Roy AC, et al.: Association of Accl polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril 2000, 74:1233-1236.
48. Takebayashi K, Takakura K, Wang H, et al.: Mutation analysis of the growth differentiation factor-9 and -9B genes in patients with premature ovarian failure and polycystic ovary syndrome. Fertil Steril 2000, 74:976-979.
49. Cohen DP, Stein EM, Li Z, et al.: Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril 1999, 72:360-363.
50. Kahsar-Miller M, Azziz R, Feingold E, et al.: A variant of the glucocorticoid receptor gene is not associated with adrenal androgen excess in women with polycystic ovary syndrome. Fertil Steril 2000, 74:1237-1240.
51. Moghrabi N, Hughes IA, Dunaif A, et al.: Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab 1998, 83:2855-2860.
52. Michelmore K, Ong K, Mason S, et al.: Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001, 55:439-446.
53. Waterworth DM, Bennett ST, Gharani N, et al.: Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997, 349:986-990. First and one of the most complete analyses of the role of the insulin gene VNTR in PCOS.
54. Calvo RM, Telleria D, Sancho J, et al.: Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril 2002, 77:666-668.
55. Sorbara LR, Tang Z, Cama A, et al.: Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome. Metabolism 1994, 43:1568-1574.
56. El Mkadem SA, Lautier C, Macari F, et al.: Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001, 50:2164-2168.
57. Tapanainen JS, Koivunen R, Fauser BC, et al.: A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1999, 84:1711-1715.
58. Kim NK, Nam YS, Ko JJ, et al.: The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation is rare in Korean women with endometriosis and polycystic ovary syndrome. Fertil Steril 2001, 75:1238-1239.
59. Oksanen L, Tiitinen A, Kaprio J, et al.: No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod 2000, 6:873-876.
60. Urbanek M, Du Y, Silander K, et al.: Variation in resistin gene promoter not associated with polycystic ovary syndrome (PCOS). Diabetes 2002, (submitted).
61. Milner CR, Craig JE, Hussey ND, et al.: No association between the -308 polymorphism in the tumor necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries. Mol Hum Reprod 1999, 5:5-9.
62. Kao L-C, Urbanek M, Driscoll D, et al.: The genetic basis of polycystic ovary syndrome. In The Polycystic Ovary. Edited by Kovas G. Cambridge: Cambridge University Press; 2000: 35-48. Complete review of PCOS candidate gene analyses through 1999.
63. Franks S, Gharani N, McCarthy M: Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001, 7:405-410. Recent review of PCOS candidate gene analyses.
64. Carey AH, Waterworth D, Patel K, et al.: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994, 3:1873-1876.
65. Franks S: Polycystic ovary-syndrome. N Engl J Med 1995, 333:853-861.
66. Dunaif A, Segal KR, Shelley DR, et al.: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41:1257-1266. Demonstrated that there is a defect of insulin action in PCOS patients independent of the effects on insulin action by obesity, metabolic derangements, or endogenous sex steroid levels.
67. Dunaif A, Xia J, Book CB, et al.: Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995, 96:801-810.
68. Ciaraldi TP, el-Roeiy A, Madar Z, et al.: Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992, 75:577-583.
69. Kiddy DS, Hamilton-Faidey D, Bush A, et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992, 36:105-111.
70. Franks S, Gharani N, McCarthy M: Genetic abnormalities in polycystic ovary syndrome. Annales d Endocrinologie 1999, 60:131-133.
71. Franks S, Gharani N, Waterworth D, et al.: Genetics of polycystic ovary syndrome. Mol Cell Endocrinol 1998, 145:123-128.
72. Crosignani PG, Nicolosi AE: Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 2001, 7:3-7.
73. Jakubiczka S, Nedel S, Werder E, et al.: Mutations of the androgen receptor gene in patients with complete androgen insensitivity. Hum Mutat 1997, 9:57-61.
74. Mhatre AN, Trifiro MA, Kaufman M, et al.: Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet 1993, 5:184-188.
75. Tut TG, Ghadessy FJ, Trifiro MA, et al.: Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997, 82:3777-3782.
76. Guo Q, Kuma TR, Woodruff T, et al.: Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 1998, 12:96-106.
77. Mather JP, Moore A, Li RH: Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc Soc Exp Biol Med 1997, 215:209-222.
78. Odunsi K, Kidd K: A paradigm for finding genes for a complex human trait: polycystic ovary syndrome and follistatin. Proc Natl Acad Sci USA 1999, 96:8315-8317.
79. Calvo RM, Villuendas G, Sancho J, et al.: Role of the follistatin gene in women with polycystic ovary syndrome. Fertil Steril 2001, 75:1020-1023.
80. Fujiwara T, Sidis Y, Welt C, et al.: Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. J Clin Endocrinol Metab 2001, 86:4206-4215.
81. Erickson GF, Chung DG, Sit A, et al.: Follistatin concentrations in follicular fluid of normal and polycystic ovaries. Hum Reprod 1995, 10:2120-2124.
82. Norman RJ, Milner CR, Groome NP, et al.: Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum Reprod 2001, 16:668-672.
83. Eldar-Geva T, Spitz IM, Groome NP, et al.: Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum Reprod 2001, 16:2552-2556.
84. Hanis CL, Boerwinkle E, Chakraborty R, et al.: A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome-2. Nat Genet 1996, 13:161-166.
85. Horikawa Y, Oda N, Cox NJ, et al.: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163-175.
86. Evans JC, Frayling TM, Cassell PG, et al.: Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001, 69:544-552.
87. Tsai HJ, Sunday G, Weeks DE, et al.: Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: no evidence of association. Am J Hum Genet 2001, 69:1236-1244.
88. Baier LJ, Permana PA, Yang X, et al.: A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000, 106:R69-73.
89. Sreenan SK, Zhou YP, Otani K, et al.: Calpains play a role in insulin secretion and action. Diabetes 2001, 50:2013-2020.
90. Huxtable SJ, Saker PJ, Haddad L, et al.: Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes 2000, 49:126-130.
91. Bennett ST, Lucassen AM, Gough SC, et al.: Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nature Genet 1995, 9:284-292.
92. Bennett ST, Wilson AJ, Cucca F, et al.: IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J Autoimmun 1996, 9:415-421.
93. Vafiadis P, Bennett ST, Colle E, et al.: Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leukocytes. J Autoimmun 1996, 9:397-403.
94. Kennedy GC, German MS, Rutter WJ: The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet 1995, 9:293-298.
95. Lucassen AM, Screaton GR, Julier C, et al.: Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum Mol Genet 1995, 4:501-506.
96. Owerbach D, Gabbay KH: The search for IDDM susceptibility genes: the next generation. Diabetes 1996, 45:544-51.
97. Bennett ST, Todd JA: Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996, 30:343-370.
98. Ong KK, Phillips DI, Fall C, et al.: The insulin gene VNTR, type 2 diabetes and birth weight. Nat Genet 1999, 21:262-263.
99. Le Stunff C, Fallin D, Schork NJ, et al.: The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. Nat Genet 2000, 26:444-446.
100. Le Stunff C, Fallin D, Bougneres P: Paternal transmission of the very common class IINS VNTR alleles predisposes to childhood obesity. Nat Genet 2001, 29:96-99.
101. Bennett ST, Todd JA, Waterworth DM, et al.: Association of insulin gene VNTR polymorphism with polycycstic ovary syndrome. Lancet 1997, 349:1771-1772.
102. Deleted in proof.
103. Hart LM, Nijpels G, Dekker JM, et al.: Variations in insulin secretion in carriers of gene variants in IRS-1 and -2. Diabetes 2002, 51:884-887.
104. Taylor SI, Cama A, Accili D, et al.: Mutations in the insulin receptor gene. Endocrine Rev 1992, 13:566-595.
105. Krook A, Kumar S, Laing I, et al.: Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 1994, 43:357-368.
106. Krook A, O'Rahilly S: Mutant insulin receptors in syndromes of insulin resistance. Baillieres Clin Endocrinol Metab 1996, 10:97-122.
107. O'Rahilly S, Choi WH, Patel P, et al.: Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. Diabetes 1991, 40:777-782.
108. Conway G, Avey C, Rumsby G: The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Hum Reprod 1994, 9:1681-1683.
109. Talbot J, Bicknell E, Rajkhewa M, et al.: Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1996, 81:1979-1983.
110. Urbanek M, Legro RS, Driscoll D, et al.: Searching for the polycystic ovary syndrome genes. J Pediatr Endocrinol Metab 2000, 13:1311-1313.
111. Elchebly M, Payette P, Michaliszyn E, et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
112. Di Paola R, Frittitta L, Miscio G, et al.: A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet 2002, 70:806-812.
113. Ravichandran LV, Chen H, Li Y, et al.: Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor. Mol Endocrinol 2001, 15:1768-1780.
114. Hoffstedt J, Andersson IL, Persson L, et al.: The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. Diabetologia 2002, 45:584-587.
115. Macut D, Micic D, Cvijovic G, et al.: Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001, 14 Suppl 5:1353-1359; discussion 1365.
116. Kondo H, Shimomura I, Matsukawa Y, et al.: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51:2325-2328.
117. Menzaghi C, Ercolino T, Di Paola R, et al.: A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002, 51:2306-2312.
118. Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
119. Stefan N, Vozarova B, Funahashi T, et al.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.